Patents by Inventor Liangyi Wan

Liangyi Wan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONJUGATES AND PREPARATION AND USE THEREOF
    Publication number: 20230257827
    Abstract: A compound for forming a conjugate with an active agent such as an oligonucleotide having a structure represented by Formula (321). The present disclosure also provides a corresponding conjugate. The conjugate of the present disclosure can specifically target hepatocytes, thereby effectively solve the problems associated with delivery of oligonucleotide drugs in vivo, and have low toxicity and excellent delivery efficiency while maintaining high stability for the delivered oligonucleotide.
    Type: Application
    Filed: March 9, 2023
    Publication date: August 17, 2023
    Applicant: SUZHOU RIBO LIFE SCIENCE CO., LTD.
    Inventors: Hongyan ZHANG, Zhiwei YANG, Liqiang CAO, Liangyi WAN
  • Conjugates and preparation and use thereof
    Patent number: 11633482
    Abstract: A compound for forming a conjugate with an active agent such as an oligonucleotide having a structure represented by Formula (321). The present disclosure also provides a corresponding conjugate. The conjugate of the present disclosure can specifically target hepatocytes, thereby effectively solve the problems associated with delivery of oligonucleotide drugs in vivo, and have low toxicity and excellent delivery efficiency while maintaining high stability for the delivered oligonucleotide.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: April 25, 2023
    Assignee: SUZHOU RIBO LIFE SCIENCE CO., LTD.
    Inventors: Hongyan Zhang, Zhiwei Yang, Liqiang Cao, Liangyi Wan
  • CONJUGATES AND PREPARATION AND USE THEREOF
    Publication number: 20200338201
    Abstract: A compound for forming a conjugate with an active agent such as an oligonucleotide having a structure represented by Formula (321). The present disclosure also provides a corresponding conjugate. The conjugate of the present disclosure can specifically target hepatocytes, thereby effectively solve the problems associated with delivery of oligonucleotide drugs in vivo, and have low toxicity and excellent delivery efficiency while maintaining high stability for the delivered oligonucleotide.
    Type: Application
    Filed: November 29, 2018
    Publication date: October 29, 2020
    Inventors: Hongyan Zhang, Zhiwei Yang, Liqiang Cao, Liangyi Wan